<-- test --!> brbc – Page 3717 – Best Reviews By Consumers

brbc

In a major setback for Durham, jury acquits former Clinton lawyer

In a major setback for Durham, jury acquits former Clinton lawyer

Over the course of several months, Donald Trump has periodically blurted out special counsel John Durham’s name, hoping the prosecutor would bolster some of the former president’s conspiracy theories. Before leaving the White House, Trump even suggested Durham’s probe could serve as a possible vehicle for retaliating against his perceived enemies. But the longer the …

In a major setback for Durham, jury acquits former Clinton lawyer Read More »

From Nike Sneakers to Jimmy Choo Swimsuits, 14 New Fashion Arrivals to Shop

From Nike Sneakers to Jimmy Choo Swimsuits, 14 New Fashion Arrivals to Shop

Inspired by the Swedish tradition of ice bathing, Filippa K debuts a blue and black collection of swimsuits and trunks for women and men. Filippa K asymmetric swimsuit Filippa K asymmetric swimsuit Filippa K long board shorts Filippa K long board shorts Find exclusive caftans and swimsuits designed by Alexandra Miro on Mytheresa’s website. Alexandra …

From Nike Sneakers to Jimmy Choo Swimsuits, 14 New Fashion Arrivals to Shop Read More »

Zuranolone Win for Postpartum Depression; Nursing Home Pills; Men & Eating Disorders

Zuranolone Win for Postpartum Depression; Nursing Home Pills; Men & Eating Disorders

Women treated with 50 mg of zuranolone showed clinically meaningful improvements in postpartum depressive symptoms by day 15 versus placebo — meeting the primary endpoint of the phase III SKYLARK study, Sage Therapeutics and Biogen announced. The agent also met all key secondary endpoints at days 3, 28, and 45. Although antipsychotic and anxiolytic prescribing …

Zuranolone Win for Postpartum Depression; Nursing Home Pills; Men & Eating Disorders Read More »

FDA Pulls Lymphoma Approvals for PI3K Inhibitor Umbralisib

FDA Pulls Lymphoma Approvals for PI3K Inhibitor Umbralisib

The FDA has withdrawn approval of the PI3K inhibitor umbralisib (Ukoniq) for marginal zone lymphoma (MZL) and follicular lymphoma because of safety concerns, the agency announced in a safety communication. The action follows an earlier safety communication about a possible increased risk of death among patients treated with umbralisib. In response to safety concerns about …

FDA Pulls Lymphoma Approvals for PI3K Inhibitor Umbralisib Read More »